|
INN name:
|
Enasidenib
|
|||||||||
|
Lab codes:
|
Appears
to be AG-221
|
|||||||||
|
Chemical name:
|
2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol
|
|||||||||
|
Molecular formula:
|
C19H17F6N7O
|
|||||||||
|
Chemical Structure:
|
 |
|||||||||
|
CAS Registry Number:
|
1446502-11-9
|
|||||||||
|
Originator:
|
Agios
Pharmaceuticals
|
|||||||||
|
Class:
|
Antineoplastics
|
|||||||||
|
Mechanism of Action:
|
Isocitrate
dehydrogenase 2 inhibitors
|
|||||||||
|
WHO ATC code:
|
L01
(Antineoplastic Agents)
|
|||||||||
|
EPhMRA code:
|
L1
(Antineoplastics)
|
|||||||||
|
Clinical Trials:
|
||||||||||
|
Product Patent
Expiry:
For patent data
contact us at drugpatentexpiry@gmail.com
|
||||||||||
Thursday 17 September 2015
Enasidenib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment